Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pediacel + Prevenar is a combination immunization regimen consisting of two separate vaccines administered together to provide broad protection against multiple serious childhood diseases. **Pediacel** is a pentavalent vaccine that protects against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive disease caused by Haemophilus influenzae type b. It contains diphtheria toxoid, tetanus toxoid, five acellular pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), fimbriae types 2 & 3], inactivated poliovirus types 1-3, and purified polyribosylribitol phosphate capsular polysaccharide from H. influenzae type b conjugated to tetanus protein[1][4][6]. The mechanism of action involves stimulating the immune system to produce antibodies against these pathogens. **Prevenar** refers to the pneumococcal conjugate vaccine; most commonly this means Prevenar 13/Prevnar 13 (pneumococcal polysaccharide serotypes conjugated individually to CRM197 protein). It provides protection against Streptococcus pneumoniae serotypes included in the vaccine by inducing an immune response via T-cell dependent mechanisms[7]. Together, this combination covers diphtheria, tetanus, pertussis, polio types 1-3, Hib disease caused by H. influenzae type b as well as invasive pneumococcal disease due to S. pneumoniae serotypes present in Prevenar.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pediacel + Prevenar.